Cardiff Oncology saw its shares nosedive following the departure of its CEO and CFO, plus questions about some Phase II data for its candidate onvansertib in first-line RAS-mutated metastatic ...

After last week's barrage of earnings , it's time for an encore, with another big chunk of the companies in the S & P 500 ...

Merck & Co., Inc. (NYSE:MRK) is among the most profitable healthcare stocks to buy. On January 21, TheFly reported that BofA ...

On January 27, Cantor Fitzgerald boosted its price target on Merck & Co., Inc. (NYSE:MRK) to $116 from $83 but kept its ...

It turns out that, among the largest 10 companies in the S&P 500 SPX healthcare sector by market capitalization, there are majority buy or equivalent ratings on nine of them, and UNH is tied with ...

This vaccine-focused biotech reported a significant insider sale as it advances its hepatitis B franchise and global ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Jan 28 (Reuters) - Eikon ‍Therapeutics, headed ‌by ​Merck veteran Roger Perlmutter, is ‌targeting a valuation of up to $908.2 ...

According to fund sponsor T. Rowe Price, managers invest in four main categories: Pharmaceuticals, health care companies, ...

Merck (NYSE:MRK) has ended acquisition talks with oncology-focused Revolution Medicines. The discussions centered on a potential multi billion dollar deal that had drawn wide industry attention. The ...

It was revealed in a recent SEC filing that Chirfi Guindo, Chief Marketing Officer at Merck & Co (NYSE: MRK) made a ...